Ítem
Acceso Abierto

Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic

Mostrar el registro sencillo de la publicación
dc.creatorKorobelnik, Jean-Françoisspa
dc.creatorLoewenstein, Anatspa
dc.creatorEldem, Boraspa
dc.creatorJoussen, Antonia M.spa
dc.creatorKoh, Adrianspa
dc.creatorLambrou, George N.spa
dc.creatorLanzetta, Paolospa
dc.creatorLi, Xiaoxinspa
dc.creatorLövestam-Adrian, Monicaspa
dc.creatorNavarro, Rafaelspa
dc.creatorOkada, Annabelle A.spa
dc.creatorPearce, Ianspa
dc.creatorRodríguez, Francisco J.spa
dc.creatorWong, David T.spa
dc.creatorWu, Lihtehspa
dc.date.accessioned2020-06-11T13:21:13Z
dc.date.available2020-06-11T13:21:13Z
dc.date.created2020-04-23spa
dc.description.abstractPurpose There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on how to deliver the best possible care for patients while minimizing the risk of infection. Methods The Vision Academy's Steering Committee of international retinal disease experts convened to discuss key considerations for managing patients with retinal disease during the COVID-19 pandemic. After reviewing the existing literature on the issue, members put forward recommendations that were systematically refined and voted on to develop this guidance. Results The considerations focus on the implementation of steps to minimize the exposure of patients and healthcare staff to COVID-19. These include the use of personal protective equipment, adherence to scrupulous hygiene and disinfection protocols, pre-screening to identify symptomatic patients, and reducing the number of people in waiting rooms. Other important measures include triaging of patients to identify those at the greatest risk of irreversible vision loss and prioritization of treatment visits over monitoring visits where possible. In order to limit patient exposure, ophthalmologists should refrain from using treatment regimens that require frequent monitoring. Conclusion Management of patients with retinal disease receiving intravitreal injections during the COVID-19 pandemic will require adjustment to regular clinical practice to minimize the risk of exposure of patients and healthcare staff, and to prioritize those with the greatest medical need. The safety of patients and healthcare staff should be of paramount importance in all decision-making.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1007/s00417-020-04703-x
dc.identifier.issn0721-832X
dc.identifier.issn1435-702X
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/24776
dc.language.isoeng
dc.publisherGraefe's Archive for Clinical and Experimental Ophthalmologyspa
dc.relation.citationEndPage8
dc.relation.citationStartPage1
dc.relation.citationTitleGraefe`s Archive for Clinical and Experimental Ophthalmology
dc.relation.ispartofGraefe's Archive for Clinical and Experimental Ophthalmology, ISSN: 0721-832X;1435-702X, No. (2020-04-23); pp. 1-8spa
dc.relation.urihttps://link.springer.com/content/pdf/10.1007/s00417-020-04703-x.pdfspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordRetinal diseasespa
dc.subject.keywordOphthalmologyspa
dc.subject.keywordCOVID-19spa
dc.subject.keywordCoronavirusspa
dc.subject.keywordRecommendationsspa
dc.subject.keywordVision Academyspa
dc.titleGuidance for anti-VEGF intravitreal injections during the COVID-19 pandemicspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
Korobelnik2020_Article_GuidanceForAnti-VEGFIntravitre.pdf
Tamaño:
379.63 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos